Hopen Life Science Ventures

Delphinus Medical Technologies, Inc. is a medical imaging company based in Plymouth, Michigan, with an additional office in Sunnyvale, California. Founded in 2009, the company specializes in developing and commercializing innovative breast cancer screening solutions. Its flagship product, SoftVue, employs a unique circular array transducer technology that utilizes ultrasound to provide three-dimensional and tomographic imaging of the entire breast. This system is designed to differentiate between benign and malignant masses, assess breast cancer risks, and monitor treatment, all while ensuring a comfortable experience for patients without the use of radiation. Delphinus serves hospitals and imaging clinics both in the United States and internationally, aiming to improve early detection and diagnosis of breast cancer.

Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. Founded in 2015 and headquartered in San Diego, California, the company is focused on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K operates as a next-generation insulin sensitizer, aiming to address the underlying pathophysiology of NASH, which is characterized by fat accumulation and inflammation in the liver and can progress to severe conditions such as cirrhosis or liver cancer. Cirius Therapeutics seeks to provide innovative solutions for healthcare providers managing liver and metabolic diseases.

Delphinus Medical Technologies, Inc. is a medical imaging company based in Plymouth, Michigan, with an additional office in Sunnyvale, California. Founded in 2009, the company specializes in developing and commercializing innovative breast cancer screening solutions. Its flagship product, SoftVue, employs a unique circular array transducer technology that utilizes ultrasound to provide three-dimensional and tomographic imaging of the entire breast. This system is designed to differentiate between benign and malignant masses, assess breast cancer risks, and monitor treatment, all while ensuring a comfortable experience for patients without the use of radiation. Delphinus serves hospitals and imaging clinics both in the United States and internationally, aiming to improve early detection and diagnosis of breast cancer.

NeoChord, Inc. is a medical technology company based in St. Louis Park, Minnesota, specializing in innovative solutions for degenerative mitral valve disease (DMR). Founded in 2007, the company has developed the NeoChord Artificial Chordae Delivery System, a proprietary device that enables mitral valve repair to be performed while the heart is still beating. This minimally invasive technique involves a small incision, significantly reducing recovery time and complications compared to traditional procedures that require larger chest incisions and stopping the heart. NeoChord's system addresses severe mitral regurgitation caused by elongated or ruptured chordae tendineae, allowing surgeons to effectively manage blood flow without the need for cardiopulmonary bypass.

Prevacept Infection Control is a clinical-stage company dedicated to developing and commercializing products aimed at preventing infections linked to indwelling catheters.

Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing targeted therapies for hematology and oncology patients. Founded in 2003 and headquartered in Vancouver, Canada, the company focuses on delivering innovative treatments for rare forms of cancer. Its lead drug candidate, momelotinib, is a selective inhibitor of JAK1, JAK2, and ACVR1, which has been evaluated in two completed Phase 3 trials for myelofibrosis. In addition, Sierra is advancing SRA737, an inhibitor of Checkpoint kinase 1 currently undergoing Phase 1/2 clinical trials, and SRA141, an inhibitor of cell division cycle 7 kinase in preclinical development. Through its scientific expertise and evidence-based approach, Sierra Oncology aims to transform cancer treatment paradigms and improve patient outcomes.

Bjond Inc. is a technology company based in Columbus, Ohio, founded in 2012. It specializes in automated workflow, real-time decision support, and behavior change software designed for both consumers and businesses across various industries. The company's innovative platform enables users, regardless of their technical expertise, to create interactive content and automated expert workflows tailored to any subject. In the healthcare sector, Bjond's software assists patients by providing dynamic decision support and promoting behavior change, ultimately fostering a continuous cycle of data-driven care that enhances patients' lives and makes the treatment process more engaging.

Tolera Therapeutics Inc. is a biotechnology company established under the leadership of Dr. Maria Siemionow, an expert in microsurgery and transplantation. Originating as a spin-off of the Cleveland Clinic, Tolera focuses on developing advanced immune modulation therapies aimed at enhancing organ and tissue transplant acceptance while minimizing the need for chronic immunosuppression. The company’s innovative approach targets the human alpha-beta T-cell receptor, which helps render pathologic T-cells inert. This unique signaling pathway promotes the expansion of regulatory T-cells in a non-depleting manner, addressing unmet medical needs for patients with a range of autoimmune and immune-mediated diseases. Through its research, Tolera Therapeutics aims to provide safer, more effective solutions that improve patient outcomes and quality of life.

Trapelo Health is a healthcare technology company based in Cambridge, Massachusetts, that specializes in precision oncology. Founded in 2009, the company has developed a collaborative decision support platform that provides evidence-based reports in molecular oncology for physicians, payers, and labs. This platform facilitates the alignment of molecular test results with associated therapies, enabling healthcare providers to efficiently identify appropriate treatments based on the latest medical evidence. Trapelo Health aims to enhance the use of precision medicine by fostering collaboration among oncologists, molecular labs, and payers, ultimately supporting effective cancer care through the analysis of cancerous tissues and the generation of genomic insights.

Metabolic Solutions Development Company, LLC is a biopharmaceutical firm focused on drug discovery and development aimed at addressing metabolic diseases associated with aging. Founded in 2006 and based in Kalamazoo, Michigan, the company is dedicated to investigating novel molecular targets for therapeutic intervention. It is developing a range of innovative oral therapeutics, including MSDC-0160 and MSDC-0602, to treat conditions such as type 2 diabetes, polycystic kidney disease, and neurodegenerative disorders like Alzheimer's and Parkinson's diseases. The company's approach involves creating non-thiazolidinedione insulin sensitizers that modulate mitochondrial function to improve metabolic control, addressing complications related to insulin resistance and other aspects of metabolic syndrome.

Base4 Biotechnology develops a small-molecule discovery platform that targets RNA structures to enable therapies for diseases across neurology, oncology, and rare diseases. The platform combines rapid in silico exploration with rigorous experimental validation to unlock RNA targets across therapeutic areas and advance RNA structure-based drug discovery toward transformative medicines.

Metabolic Solutions Development Company, LLC is a biopharmaceutical firm focused on drug discovery and development aimed at addressing metabolic diseases associated with aging. Founded in 2006 and based in Kalamazoo, Michigan, the company is dedicated to investigating novel molecular targets for therapeutic intervention. It is developing a range of innovative oral therapeutics, including MSDC-0160 and MSDC-0602, to treat conditions such as type 2 diabetes, polycystic kidney disease, and neurodegenerative disorders like Alzheimer's and Parkinson's diseases. The company's approach involves creating non-thiazolidinedione insulin sensitizers that modulate mitochondrial function to improve metabolic control, addressing complications related to insulin resistance and other aspects of metabolic syndrome.